A New Prothrombotic Pathway Emerges in Antiphospholipid Syndrome
A study published in *Arthritis & Rheumatology* reveals a novel mechanism driving platelet hyperactivation in antiphospholipid syndrome (APS), an autoimmune disorder characterized by thrombosis and pregnancy complications. Researchers found that platelets from APS patients exhibit significantly higher basal release of ATP, a key signaling molecule, through pannexin-1 (PANX1) channels. This ATP release, triggered by APS autoantibodies, activates P2X receptors in a calcium-dependent feedback loop, amplifying platelet activation, P-selectin expression, and aggregation. The study demonstrated that inhibiting PANX1 channels with carbenoxolone normalized this prothrombotic phenotype, suggesting a potential new therapeutic target that could curb thrombosis without impairing normal hemostasis.
Why it might matter to you:
This research identifies PANX1 as a central mediator in APS-related thrombosis, moving beyond traditional anticoagulant strategies. For rheumatologists managing this complex autoimmune disease, these findings highlight a specific cellular pathway that could be targeted to reduce thrombotic risk. It underscores the importance of exploring platelet biology in autoimmune conditions and may inform the development of next-generation, mechanism-driven therapies for APS.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.